GSK Settles U.S. Zantac Lawsuits for Up to $2.2 Billion, Resolves 80,000 Cases

GSK (GSK.L), has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.

The agreement with 10 plaintiffs’ law firms resolves about 80,000 cases, or 93% of cases pending against the British drugmaker in state courts nationwide, the company said. GSK also said it would pay $70 million to settle a related whistleblower lawsuit filed by a Connecticut laboratory.

Read more at Reuters.